PURPOSE: Primary cutaneous B-cell lymphomas (PCBCLs) are a distinct group of primary cutaneous lymphomas with few and conflicting data on their prognostic factors. PATIENTS AND METHODS: The study group included 467 patients with PCBCL who were referred, treated, and observed in 11 Italian centers (the Italian Study Group for Cutaneous Lymphomas) during a 24-year period (1980 to 2003). All of the patients were reclassified according to the WHO-European Organisation for Research and Treatment of Cancer (EORTC) classification. RESULTS: Follicle center lymphoma (FCL) accounted for 56.7% of occurrences, followed by marginal-zone B-cell lymphoma (MZL; 31.4%); diffuse large B-cell lymphoma (DLBCL), leg type, was reported in 10.9% of patients. Radiotherapy was the first-line treatment in 52.5% of patients and chemotherapy was the first-line treatment in 24.8% of patients. The complete response rate was 91.9% and the relapse rate was 46.7%. The 5- and 10-year overall survival (OS) rates were 94% and 85%, ...
Principal cutaneous B-cell lymphomas are a heterogeneous group of older B-cells neoplasms with tropism for the epidermis, whose biology and clinical training course differ from the equal nodal lymphomas significantly. huge B-cell lymphomas. Treatment might consist of operative excision, radiotherapy, antibiotics, corticosteroids, interferon, monoclonal chemotherapy and antibodies, depending upon the type of lymphoma and upon the area and type of the epidermis lesions. In subtypes with great treatment is certainly KIAA1516 contraindicated overtreatment and in those linked with a even worse treatment the suggested therapy depends on CHOP-like routines linked with rituximab, helped or not really with regional radiotherapy. We critique the principal cutaneous B-cell lymphomas, knowing how the analysis requirements, differential medical diagnosis, category, and prognostic elements and introducing the obtainable therapies. infections, although the subject is controversy still. 15-21 Cutaneous B-cell ...
One classification system for lymphomas divides the diseases according to the size of the white blood cells that has turned cancerous. The large-cell lymphomas have large cells. A large cell, in this context, has a diameter of 17 to 20 µm. Other groups of lymphomas in this system are the small-cell lymphomas and mixed-cell lymphomas. Diffuse large B-cell lymphoma is the most common of the large-cell lymphomas. MeSH now classifies the phrase large-cell lymphoma under Diffuse large B cell lymphoma. Many other B-cell lymphomas feature large cells: Angiocentric lymphoma Burkitts lymphoma Follicular large-cell lymphoma Immunoblastic lymphoma Intravascular large-cell lymphoma Primary mediastinal B-cell lymphoma T-cell-rich B-cell lymphoma Primary splenic lymphoma (rare) Primary central nervous system lymphomas, which are often diffuse large-B-cell lymphomas Activated B-Cell Diffuse Large B-Cell Lymphoma, or ABC-DLBCL, is believed to be caused by aberrant activation of a critical intracellular ...
TY - JOUR. T1 - Adult high-grade B-cell lymphoma with Burkitt lymphoma signature. T2 - Genomic features and potential therapeutic targets. AU - Bouska, Alyssa. AU - Bi, Chengfeng. AU - Lone, Waseem. AU - Zhang, Weiwei. AU - Kedwaii, Ambreen. AU - Heavican, Tayla. AU - Lachel, Cynthia M.. AU - Yu, Jiayu. AU - Ferro, Roberto. AU - Eldorghamy, Nanees. AU - Greiner, Timothy Charles. AU - Vose, Julie Marie. AU - Weisenburger, Dennis D.. AU - Gascoyne, Randy D.. AU - Rosenwald, Andreas. AU - Ott, German. AU - Campo, Elias. AU - Rimsza, Lisa M.. AU - Jaffe, Elaine S.. AU - Braziel, Rita M.. AU - Siebert, Reiner. AU - Miles, Rodney R.. AU - Dave, Sandeep. AU - Reddy, Anupama. AU - Delabie, Jan. AU - Staudt, Louis M.. AU - Song, Joo Y.. AU - McKeithan, Timothy W.. AU - Fu, Kai. AU - Green, Michael. AU - Chan, Wing C.. AU - Iqbal, Javeed. PY - 2017/10/19. Y1 - 2017/10/19. N2 - The adult high-grade B-cell lymphomas sharing molecular features with Burkitt lymphoma (BL) are highly aggressivelymphomas with ...
TY - JOUR. T1 - Indolent B-Cell lymphomas associated with HCV infection. T2 - Clinical and virological features and role of antiviral therapy. AU - Arcaini, Luca. AU - Merli, Michele. AU - Volpetti, Stefano. AU - Rattotti, Sara. AU - Gotti, Manuel. AU - Zaja, Francesco. PY - 2012. Y1 - 2012. N2 - The association between hepatitis C virus (HCV) infection and B-cell non-Hodgkins lymphomas (NHL) has been demonstrated by epidemiological studies, in particular in highly endemic geographical areas such as Italy, Japan, and southern parts of United States. In these countries, together with diffuse large B-cell lymphomas, marginal zone lymphomas are the histotypes most frequently associated with HCV infection; in Italy around 2030 cases of marginal zone lymphomas are HCV positive. Recently, antiviral treatment with interferon with or without ribavirin has been proved to be effective in the treatment of HCV-positive patients affected by indolent lymphoma, prevalently of marginal zone origin. An ...
Histology: Diagnosis of aggressive CD20+, confirmed by an excisional biopsy of a lymph node or by a sufficiently extensive biopsy of an extranodal involvement if there is no lymph node involvement. It will be possible to treat the following entities in this study as defined by the new WHO classification of 2008: B-NHL, Follicular lymphoma grade IIIb,DLBCL, not otherwise specified (NOS),common morphologic variants: centroblastic,immunoblastic,anaplastic,rare morphologic variants.DLBCL subtypes/entities:T cell/histiocyte rich large B-cell lymphoma, primary cutaneous DLBCL, leg type, EBV-positive DLBCL of the elderly, DLBCL associated with chronic inflammation, primary mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma,ALK-positive large B-cell lymphoma, Plasmoblastic lymphoma, Primary effusion lymphoma, B-cell lymphoma, unclassifiable, with features inter¬mediate between diffuse large B-cell lymphoma and Burkitt lymphoma, B-cell lymphoma, unclassifiable, with features ...
RnRMarketResearch.com adds report B-Cell Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2014 to its store.. B-Cell Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2014. Summary. GlobalDatas clinical trial report, B-Cell Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2014″ provides data on the B-Cell Non-Hodgkin Lymphoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on B-Cell Non-Hodgkin Lymphoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating B-Cell Non-Hodgkin Lymphoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis ...
In 2000, Cerroni et al1 first reported primary cutaneous spindle-cell B-cell lymphoma as a rare variant of primary cutaneous B-cell lymphoma characterized by admixed centrocytes and centroblasts with spindle-shaped, elongated nuclei and in some foci a boomerang-like or spermatozoa-like morphology. Subsequently, studies reappraised this entity as a special subtype of primary cutaneous follicle center lymphoma.3,5,6 Ries et al14 reported the only Bcl-6-negative spindle-cell B-cell lymphoma. However, that particular case was not fulfilling the criteria of Cerroni et al.1 The skin is most frequently affected, with 18 cases reported.1-6,8,11,13,14 The liver, vagina, and uterus were also affected in isolated cases.7,9,10 Primary cutaneous spindle-cell B-cell lymphoma shares several clinicopathologic features with primary cutaneous follicle center cell lymphoma. It typically affects elderly people with no apparent sex difference. It usually presents as single or occasionally multiple lesions on the ...
Specify your expertise for the Disease/group of diseases (eg SCT, Molecular diagnosis): Novel agents, immunotherapy, biomarkers, phase I-III clinical trials Diseases: Tumor of hematopoietic and lymphoid tissues Lymphoid hemopathy Post-transplant lymphoproliferative disease Lymphoma Non-Hodgkin lymphoma Acute lymphoblastic leukemia Precursor B-cell acute lymphoblastic leukemia Precursor T-cell acute lymphoblastic leukemia Mature B-cell acute lymphoblastic leukemia B-cell non-Hodgkin lymphoma Indolent B-cell non-Hodgkin lymphoma Follicular lymphoma Waldenström macroglobulinemia Hairy cell leukemia B-cell chronic lymphocytic leukemia Indolent primary cutaneous B-cell lymphoma Primary cutaneous marginal zone B-cell lymphoma Primary cutaneous follicle center lymphoma Hairy cell leukemia variant Marginal zone lymphoma MALT lymphoma Splenic marginal zone lymphoma Nodal marginal zone B-cell lymphoma Splenic diffuse red pulp small B-cell lymphoma Lymphoplasmacytic lymphoma without IgM production ...
TY - JOUR. T1 - Outcomes among North American patients with diffuse large b-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression. AU - Tracy, Sean I.. AU - Habermann, Thomas Matthew. AU - Feldman, Andrew L. AU - Maurer, Matthew J.. AU - Dogan, Ahmet. AU - Perepu, Usha S.. AU - Syrbu, Sergei. AU - Ansell, Stephen Maxted. AU - Thompson, Carrie A. AU - Weiner, George J.. AU - Nowakowski, Grzegorz S. AU - Allmer, Cristine. AU - Slager, Susan L. AU - Witzig, Thomas Elmer. AU - Cerhan, James R. AU - Link, Brian K.. PY - 2018/1/31. Y1 - 2018/1/31. N2 - The prevalence, presenting clinical and pathological characteristics, and outcomes for patients with diffuse large B-cell lymphoma that is Epstein-Barr virus positive remain uncertain as does the impact of congenital or iatrogenic immunosuppression. Patients with newly diagnosed diffuse large B-cell lymphoma with available tissue arrays were identified from the University of Iowa/Mayo Clinic Molecular Epidemiology ...
What types of high-grade B-cell lymphomas are difficult to classify? There are lots of different types of lymphoma. The tests you have when you are diagnosed help your medical team find out which type of lymphoma you have. This is called classifying your lymphoma.
TY - JOUR. T1 - A Case of cutaneous large B-cell lymphoma during treatment of multiple sclerosis with fingolimod. AU - Stitt, Derek W.. AU - Boes, Christopher J.. AU - Flanagan, Eoin. AU - Howard, Matthew T.. AU - Colgan, Joseph P.. PY - 2018/1/1. Y1 - 2018/1/1. N2 - The authors report a case of a 69-year-old woman with multiple sclerosis treated with fingolimod for duration of over one year who subsequently developed cutaneous large B cell lymphoma. There are few reported cases of lymphoma associated with fingolimod treatment for multiple sclerosis, but rates are higher than expected in the general population. The authors hope to promote awareness of the potential risk of this medication so that more diligent disease surveillance can be performed by both prescribing practitioners of fingolimod and their patients who receive it.. AB - The authors report a case of a 69-year-old woman with multiple sclerosis treated with fingolimod for duration of over one year who subsequently developed cutaneous ...
In situ follicular neoplasia (ISFN) is the earliest morphologically identifiable precursor of follicular lymphoma (FL). Although it is genetically less complex than FL and has low risk for progression, ISFN already harbors secondary genetic alterations, in addition to the defining t(14;18)(q32;q21) translocation. FL, in turn, frequently progresses to diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). By BCL2 staining of available reactive lymphoid tissue obtained at any time point in patients with aggressive B-cell lymphoma (BCL), we identified 10 paired cases of ISFN and DLBCL/HGBL, including 6 de novo tumors and 4 transformed from FL as intermediate step, and investigated their clonal evolution using microdissection and next generation sequencing. A clonal relationship between ISFN and aggressive BCL was established by immunoglobulin and/or BCL2 rearrangements and/or the demonstration of shared somatic mutations for all 10 cases. Targeted sequencing revealed CREBBP, ...
Sborník Background. Diffuse large B-cell lymphoma (DLBCL), a heterogeneous clinicopathologic entity, accounts for up to 40% of non-Hodgkins lymphomas. Gene expression profiling confirmed the presence of three molecular prognostic subgroups - germinal center B-cell-like (GCB), activated B-cell-like (ABC) and primary mediastinal B-cell lymphoma (PMBL). Nevertheless, there is a need to...
BACKGROUND: An association between Borrelia burgdorferi and cutaneous B-cell lymphoma (CBCL) has been made in several European countries. The evidence in favor of such an association has recently been based on more definitive tests for the pathogenetic role of B. burgdorferi in CBCL, including positive cultures or polymerase chain reaction (PCR) amplification of borrelial DNA from lesional skin. However, there is only one report of B. burgdorferi in four North American cases of B-cell lymphoma. METHODS: We retrieved 38 cases of primary and secondary CBCL from different geographic regions of the United States. Two separate techniques were used to detect borrelial DNA by PCR, a nested PCR method to amplify a B. burgdorferi-specific gene as well as a borrelial chromosomal Ly-1 clone amplification method. Southern blot hybridization was used for confirmation of the PCR results. RESULTS: No B. burgdorferi-specific DNA was detected in any of the 38 CBCL cases, whereas detectable PCR products were obtained
Background Although chemo-immunotherapy has led to an improved overall survival for most B-cell lymphoma types, relapsed and refractory disease remains a challenge. The malaria drug artesunate has previously been identified as a growth suppressor in some cancer types and was tested as a new treatment option in B-cell lymphoma. Methods We included artesunate in a cancer sensitivity drug screen in B lymphoma cell lines. The preclinical properties of artesunate was tested as single agent in vitro in 18 B-cell lymphoma cell lines representing different histologies and in vivo in an aggressive B-cell lymphoma xenograft model, using NSG mice. Artesunate-treated B lymphoma cell lines were analyzed by functional assays, gene expression profiling, and protein expression to identify the mechanism of action. Results Drug screening identified artesunate as a highly potent anti-lymphoma drug.Artesunate induced potent growth suppression in most B lymphoma cells with an IC50 comparable to concentrations ...
Diffuse large B-cell lymphoma (DLCBL) is the most frequent form of lymphoid cancer, accounting for 30% to 35% of all nodal lymphomas.1 Based on gene expression profiling (GEP), 3 distinct subtypes of DLBCL have been identified, namely the germinal center (GC) B-cell (GCB), activated B-cell (ABC), and primary mediastinal B-cell lymphoma subtypes.2 The ABC subtype of DLBCL is characterized by adverse prognosis and constitutive activation of the transcription factor nuclear factor-κB (NF-κB).3 This is thought to be the consequence of somatic mutations in the genes encoding the B-cell receptor (BCR)-associated CD79A and CD79B chains,4 or the BCR signal transducer caspase recruitment domain-containing membrane-associated guanylate kinase-1 (CARMA1) (also known as CARD11),5 and polymorphisms in RNF31 (also known as HOIP),6 which result in constitutive BCR signaling. These can be present alone or in combination with activating mutations in genes encoding the Toll-like receptor (TLR) downstream ...
COPYRIGHT (C) 2016 KISTI. ALL RIGHTS RESERVED.. 대전광역시 유성구 대학로 245 한국과학기술정보연구원TEL : 042.869.1234 서울시 동대문구 회기로 66NDSL고객센터 : 080.969.4114E-mail : [email protected] ...
MONDAY, Dec. 11, 2017 (HealthDay News) - Axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy and autologous T cells that express a CD19-directed CAR (CTL019) are effective for refractory B-cell lymphomas, according to two studies published online Dec. 10 in the New England Journal of Medicine to coincide with the annual meeting of the American Society of Hematology, held from Dec. 9 to 12 in Atlanta.. Sattva S. Neelapu, M.D., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues enrolled 111 patients with diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, or transformed follicular lymphoma with refractory disease despite receiving prior therapy. A target dose of 2×106 anti-CD19 CAR T cells/kg body weight was administered to 101 patients. The researchers found that the objective and complete response rates were 82 and 54 percent, respectively. Overall, 42 percent of the patients continued to have a ...
The B-cell lymphomas are types of lymphoma affecting B cells. Lymphomas are blood cancers in the lymph nodes. They develop more frequently in older adults and in immunocompromised individuals. B-cell lymphomas include both Hodgkins lymphomas and most non-Hodgkin lymphomas. They are typically divided into low and high grade, typically corresponding to indolent (slow-growing) lymphomas and aggressive lymphomas, respectively. As a generalisation, indolent lymphomas respond to treatment and are kept under control (in remission) with long-term survival of many years, but are not cured. Aggressive lymphomas usually require intensive treatments, with some having a good prospect for a permanent cure. Prognosis and treatment depends on the specific type of lymphoma as well as the stage and grade. Treatment includes radiation and chemotherapy. Early-stage indolent B-cell lymphomas can often be treated with radiation alone, with long-term non-recurrence. Early-stage aggressive disease is treated with ...
What is it? Also known as … Cutaneous B-cell Lymphoma What is Primary Ctaneous B-cell Lymphoma (PCBCL)? Tumours of the lymph nodes and lymphatic system are called lymphomas. B-cell lymphomas are caused by an excess of B-cell lymphocytes, a type of white blood cell. Primary cutaneous B-cell lymphomas (PCBCL) are a group of B-cell lymphomas […]. ...
TY - JOUR. T1 - Ratios of Four STAT3 Splice Variants in Human Eosinophils and Diffuse Large B Cell Lymphoma Cells.. AU - Turton, Keren. AU - Mosher, Deane. AU - Annis, Douglas. AU - Rui, Lixin. AU - Esnault, Stephane. PY - 2015/5/18. Y1 - 2015/5/18. N2 - Signal transducer and activator of transcription 3 (STAT3) is a key mediator of leukocyte differentiation and proliferation. The 3 end of STAT3 transcripts is subject to two alternative splicing events. One results in either full-length STAT3α or in STAT3β, which lacks part of the C-terminal transactivation domain. The other is at a tandem donor (5) splice site and results in the codon for Ser-701 being included (S) or excluded (ΔS). Despite the proximity of Ser-701 to the site of activating phosphorylation at Tyr-705, ΔS/S splicing has barely been studied. Sequencing of cDNA from purified eosinophils revealed the presence of four transcripts (S-α, ΔS-α, S-β, and ΔS-β) rather than the three reported in publically available databases ...
Dermoscopy is a non invasive diagnostic method. Dermoscopedia is the online resource for dermoscopy and is provided by the international dermoscopy society. This is page „Cutaneous B-cell lymphoma
Primary cutaneous follicle center lymphoma, marginal zone lymphoma, and diffuse large b-cell lymphoma, were 3 subgroups assessed in a 2021 update.
Extranodal presentation of B-cell lymphoma is uncommon. Isolated primary epiglottic B-cell lymphoma is even rarer. To our knowledge, there has been only one description of isolated B-cell lymphoma presenting as a large epiglottic mass. We report an unusual type of B-cell lymphoma of the epiglottis, as it could not be subtyped based on routine staining and hybridization. The lymphoma presented as a large isolated globular mass pedicled to the epiglottis, occupying most of the oropharynx, but did not have any ball-valving effect or increased respiratory efforts. Initial radiographic findings were nonspecific. The diagnosis of B-cell lymphoma was determined by transoral incisional biopsy under local anesthesia. The condition was treated successfully with chemoradiation. The current standard of treatment for high grade B-cell lymphoma is concurrent chemoradiotherapy, with excellent prognosis. Although rare, B-cell lymphoma should be considered when investigating pedunculated hypopharyngeal masses.
Chimeric antigen receptor T-cells are a novel class of anti-cancer therapy in which autologous or allogeneic T-cells are engineered to express a chimeric antigen receptor targeting a membrane antigen. In Europe, Tisagenlecleucel (KymriahTM) is approved for the treatment of refractory/relapsed Acute Lymphoblastic Leukaemia in children and young adults as well as relapsed/refractory Diffuse Large B-cell Lymphoma; Axicabtagene ciloleucel (YescartaTM) is approved for the treatment of relapsed/refractory high-grade B-cell Lymphoma and Primary Mediastinal B-cell Lymphoma. Both agents are genetically engineered autologous T-cells targeting CD19. These practical recommendations, prepared under the auspices of the European Society of Blood and Marrow Transplantation, relate to patient care and supply chain management under the following headings: patient eligibility, screening laboratory tests and imaging and work-up prior to leukapheresis, how to perform leukapheresis, bridging therapy, lymphodepleting ...
Zhang, Y, et al. (2012) LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas. Blood. 2012 Aug 23; 120(8):1678-86. PM ID: ...
Researchers affiliated with the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) have reported that conventional chemoimmunotherapy was superior to sequential high-dose chemotherapy with autologous stem cell support for the treatment of high-risk patients with aggressive B-cell lymphoma. The details of this randomized study were presented at the 2011 meeting of the American Society of Clinical Oncology.. Non-Hodgkins lymphoma (NHL) is a form of cancer that begins in the cells of the lymph system. The lymph system includes the spleen, thymus, tonsils, bone marrow, lymph nodes, and circulating immune cells. The main cells in the lymph system are lymphocytes, of which there are two types: B- and T-cells. Each cell type has a specific function in helping the body fight infection.. Non-Hodgkins lymphoma is characterized by the excessive accumulation of atypical (cancerous) lymphocytes. These lymphocytes can crowd the lymph system and suppress the formation and function of other immune ...
OUTLINE: This is a multicenter study.. Blood and tissue samples collected at the time of diagnosis are analyzed for serum free light chain and clonal immunoglobulin (Ig) DNA rearrangements and circulating clonotypic B-cells via PCR.. PROJECTED ACCRUAL: A total of 50 patients (25 with diffuse large B-cell/immunoblastic histologies, 15 with Burkitt lymphoma, and 10 with Hodgkin lymphoma) will be accrued for this study. ...
Fingerprint Dive into the research topics of High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: The role of flow cytometry versus cytology. Together they form a unique fingerprint. ...
The most frequent mature aggressive B-cell lymphomas are diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL). Patients suffering from molecularly defined BL (mBL) but treated with a regimen developed for DLBCL show an unfavorable outcome compared to mBL treated with chemotherapy regimens for BL. Distinguishing BL from DLBCL by conventional histopathology is challenging in lymphomas that have features common to both diseases (aggressive B-cell lymphoma unclassifiable with features of DLBCL and BL [intermediates]). Moreover, DLBCL are a heterogeneous group of lymphomas comprising distinct molecular subtypes: the activated B-cell (ABC)-like, the germinal center B-cell-like (GCB) and the unclassifyable subtype as defined by gene expression profiling (GEP). Attempts to replace GEP with techniques applicable to formalin-fixed paraffin-embedded (FFPE) tissue led to algorithms for immunohistochemical stainings (IHS). Disappointingly, the algorithms yielded conflicting results with respect to ...
Species: Human Category: Cancer Tissue of Origin: B-cell / Plasma Cell Cancer Type: B-cell Non-Hodgkin Lymphoma Description SK-LY-18 is a human lymphoma cell line. Source This cell line was established from a B-cell in a person with lymphoma
Ricerca Primary cutaneous B-cell lymphomas (PCBCLs) comprise a group of extranodal B-cell non-Hodgkin lymphomas B-cell derived, which primarily involve the skin without evidence of extracutaneous disease at the time of diagnosis.... Leggi tutto ...
We present an extensive characterization of 10 B-cell lymphomas with a t(9;14)(p13;q32). The presence of the PAX5/IGH gene rearrangement was demonstrated by fluorescence in situ hybridization (FISH) using a validated probe set, whereas complex karyotypic changes were reassessed by multiplex-FISH (M-FISH). Pathologic and clinical review revealed the presence of this rearrangement in 4 histiocyte-rich, T-cell-rich B-cell lymphomas (HRTR-BCLs) and 2 posttransplantation diffuse large B-cell lymphomas (PTLD-DLBCLs). In contrast to initial observations describing this translocation in lymphoplasmacytic lymphoma (LPL) and LPL-derived large B-cell lymphoma, our data showed a wide morphologic and clinical spectrum associated with the PAX5/IGH rearrangement, pointing to an association between this aberration and a subset of de novo DLBCLs presenting with advanced disease and adverse prognosis. In addition, the recurrent incidence of this rearrangement in both HRTR-BCL (4 cases) and PTLD-DLBCL (2 cases) ...
The incidences of type 2 diabetes mellitus and many cancers are rapidly increasing worldwide. Diabetes is a strong risk factor for some cancers (including lymphomas) and is also associated with adverse cancer outcomes. After gastrointestinal tract, the skin is the second most frequent extranodal site involved by non-Hodgkin lymphomas and the cutaneous B-cell lymphomas (CBCLs) range from 25% to 30% of all primary cutaneous lymphomas. The primary cutaneous diffuse large B-cell lymphoma (PCDLBCL) is an aggressive lymphoma with a poor prognosis, representing roughly 20% of all primary CBCLs. Classically, the cutaneous manifestation of this lymphoma is a red or violaceous tumors arising on a leg. To date, despite the large body of evidence suggesting that diabetes is strongly associated with an increased risk of some cancers, very little information is available regarding a possible association between type 2 diabetes and primary cutaneous diffuse large B-cell lymphoma. In this report, we will ...
The incidences of type 2 diabetes mellitus and many cancers are rapidly increasing worldwide. Diabetes is a strong risk factor for some cancers (including lymphomas) and is also associated with adverse cancer outcomes. After gastrointestinal tract, the skin is the second most frequent extranodal site involved by non-Hodgkin lymphomas and the cutaneous B-cell lymphomas (CBCLs) range from 25% to 30% of all primary cutaneous lymphomas. The primary cutaneous diffuse large B-cell lymphoma (PCDLBCL) is an aggressive lymphoma with a poor prognosis, representing roughly 20% of all primary CBCLs. Classically, the cutaneous manifestation of this lymphoma is a red or violaceous tumors arising on a leg. To date, despite the large body of evidence suggesting that diabetes is strongly associated with an increased risk of some cancers, very little information is available regarding a possible association between type 2 diabetes and primary cutaneous diffuse large B-cell lymphoma. In this report, we will ...
Read Epstein-Barr virus-mediated protection against etoposide-induced apoptosis in BJA-B B cell lymphoma cells: role of Bcl-2 and caspase proteins, Archives of Virology on DeepDyve, the largest online rental service for scholarly research with thousands of academic publications available at your fingertips.
Daniel C. McFarland, DO; Joshua Brody, MD; Joseph Tripodi, MsS; Issa Leonard, BS; Vesna Najfeld, PhD. Mechanism of Action/Pathway Profiles. Remission in aggressive B-cell lymphomas is increasingly linked to complex karyotypes and gene rearrangements that often portend aggressive behavior and resistance to standard therapy. An understanding of lymphoma cytogenetics has lagged behind that of leukemia, in which pretreatment karyotype constitutes an independent prognostic determinant for attainment of complete remission. In 2008, the World Health Organization added the category B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma (BCLu-DLBCL/BL), which incorporates aggressive lymphomas with variable morphology. However, this category is nonspecific and does not elevate cytogenetic criteria to a diagnostic status based on chromosomal abnormalities as seen in acute leukemia. In part, this could be because cytogenetic analyses or ...
Based on the assumption that molecular mechanisms involved in cancerogenesis are characterized by groups of coordinately expressed genes, we developed and validated a novel method for analyzing transcriptional data called Correlated Gene Set Analysis (CGSA). Using 50 extracted gene sets we identified three different profiles of tumors in a cohort of 364 Diffuse large B-cell (DLBCL) and related mature aggressive B-cell lymphomas other than Burkitt lymphoma. The first profile had high level of expression of genes related to proliferation whereas the second profile exhibited a stromal and immune response phenotype. These two profiles were characterized by a large scale gene activation affecting genes which were recently shown to be epigenetically regulated, and which were enriched in oxidative phosphorylation, energy metabolism and nucleoside biosynthesis. The third and novel profile showed only low global gene activation similar to that found in normal B cells but not cell lines. Our study ...
Lanier, L L.; Lynes, M; Haughton, G; and Wettstein, P J., Noval type of murine b-cell lymphoma. (1978). Subject Strain Bibliography 1978. 1670 ...
Signs of B-cell lymphomas including medical signs and symptoms of B-cell lymphomas, symptoms, misdiagnosis, tests, common medical issues, duration, and the correct diagnosis for B-cell lymphomas signs or B-cell lymphomas symptoms.
Double-hit lymphomas and double-expressor lymphomas are some of the most difficult non-Hodgkin lymphomas to treat. Patients with these types of lymphomas, which are subtypes of diffuse large B-cell lymphoma, dont respond as well to chemotherapy treatment as other lymphoma patients do.. An estimated 22,000 patients nationwide are diagnosed with diffuse large B-cell lymphoma each year. About 5 to 10 percent have double-hit lymphoma (or cancer cells that contain chromosomal rearrangements of the MYC, BCL2 and/or BCL6 genes) and about 20 to 30 percent have double-expressor lymphoma (containing the MYC and BCL2 genes).. Which is why Alex F. Herrera, M.D., an assistant professor in City of Hopes Department of Hematology and Hematopoietic Cell Transplantation, and a team of doctors at City of Hope and the Dana-Farber Cancer Institute examined how well patients whose double-hit and/or double-expressor lymphoma had recurred, or was resistant to initial treatment, fared after they had received high-dose ...
【市場調査資料】CAR-T r/r B-cell NHLの世界市場予測 | 発行日:2017年8月 | 商品コード:VACZ712009 | 発行/リサーチ会社:VacZine Analytics | CAR-T r/r B-cell NHL global market forecast | キーワード:グローバル、製薬、 [世界の市場(産業/企業/技術/製品/サービス)調査・情報ならグローバルリサーチ]
Primary mediastinal B-cell lymphoma (PMBL) is characterized by aberrant activation of JAK/STAT-signaling resulting in constitutive presence of phosphorylated STAT6 (pSTAT6). identified five STAT-binding-sites in the promoter. We confirmed STAT6 binding to the promoter and by band shift / super shift assays and chromatin immunoprecipitationsUsing luciferase reporter assays, depletion of STAT6 by siRNA, and ectopic overexpression of a constitutive active STAT6 mutant, we proved that pSTAT6 is sufficient to transcriptionally KLF5 repress BCL6. Recently developed small molecule inhibitors 79-6 and TG101348 that increases BCL6 target gene expression and decreases pSTAT6 levels, respectively, demonstrate that a combined targeting results in additive efficacy regarding their negative effect on cell viability. The delineated pSTAT6-mediated molecular repression mechanism links JAK/STAT to BCL6-signaling in PMBL and may carry therapeutic potential. amplifications that established PMBL as a genetically ...
Primary Mediastinal B-Cell Lymphoma (or PMBCL for short), is a very rare form of cancer. At this point, I think I have found and read every article or scientific study written about PMBCL. There are not that many in fact, as it was only designated as its own entity in 2008 (prior to this it…
TY - JOUR. T1 - C-Myc immunohistochemistry in diffuse large B cell lymphoma. AU - Gocke, Christopher D.. PY - 2014/12/10. Y1 - 2014/12/10. N2 - Diffuse large B cell lymphoma is a collection of different biologic entities with a common appearance but different clinical behaviors. The MYC oncogene is mutated in a subset of diffuse large B cell lymphoma and is also mutated in related entities such as Burkitt lymphoma. Recently, an antibody to the c-Myc oncoprotein has become available for immunohistochemistry, raising the possibility of a rapid, reproducible and inexpensive measure of MYC abnormality. Initial retrospective studies of these lymphomas suggest that the c-Myc status is clinically important for diagnosis and prognosis, particularly when used in conjunction with BCL2 immunohistochemistry. It is possible that therapy will be modified based in part on c-Myc status, once the appropriate prospective studies have been performed.. AB - Diffuse large B cell lymphoma is a collection of different ...
While NFKBIE deletions were relatively rare in patients diagnosed with follicular lymphoma (3/225 [1.3%]), splenic marginal zone lymphoma (3/175 [1.7%]), and T-cell acute lymphoblastic leukemia (1/94 [1.1%]), slightly higher frequencies were detected among DLBCL (18/520 [3.5%]), mantle cell lymphoma (8/189 [4.2%]), primary central nervous system lymphoma (1/34 [2.9%]), and small lymphocytic lymphoma (1/9 [11.1%]). In contrast, PMBL patients showed a marked enrichment, with 46 of 203 cases harboring a NFKBIE deletion (22.7% vs 2.9% [38/1257 in other entities]; P , .001; Figure 1A). Notably, the prevalence of NFKBIE-deleted PMBL cases was independent of contributing center (supplemental Table 3).. In an ongoing exome sequencing analysis of microdissected HRS cells in cHL, we obtained indication for NFKBIE mutations in 4 out of 11 cases. From these 4 cases, we isolated HRS cells and confirmed somatic NFKBIE aberrations (1 deletion and 2 missense mutations) in 3 out of 4 cases by Sanger sequencing ...
A dose-adjusted, infusion approach to aggressive chemotherapy with Rituxan® (rituximab) may allow patients with primary mediastinal B-cell lymphoma to skip radiation, according to the results of a study published in the New England Journal of Medicine.. Non-Hodgkins lymphoma (NHL) refers to a group of cancers that originate in different cells of the immune system. Diffuse large B-cell NHL (DLBCL) is a common type of NHL that affects immune cells called B-cells; it is considered an aggressive type of NHL. Primary mediastinal B-cell lymphoma is a distinct subtype of DLBCL that is closely related to nodular sclerosing Hodgkins lymphoma. Patients are usually young and present with large mediastinal masses. There is no standard treatment-and because immunochemotherapy alone has proven inadequate, some patients are treated with consolodiation with radiation, which has potentially serious late effects.. In an attempt to improve cure rates and prevent the need for radiation in this population, ...
TY - JOUR. T1 - Constitutive activation of extracellular signal-regulated kinase predisposes diffuse large B-cell lymphoma cell lines to CD40-mediated cell death.. AU - Hollmann, C Annette. AU - Owens, Trevor. AU - Nalbantoglu, Josephine. AU - Hudson, Thomas J. AU - Sladek, Robert. PY - 2006/4/1. Y1 - 2006/4/1. N2 - CD40 promotes survival, proliferation, and differentiation of normal B cells but can cause activation-induced cell death in malignant B lymphocytes. CD40 ligand and anti-CD40 antibodies have been used successfully to induce apoptosis in lymphoma lines both in vitro and in xenograft tumor models. Although this makes CD40 an attractive target for antitumor therapies, the response of malignant B cells to CD40 signaling is variable, and CD40 stimulation can enhance proliferation and can increase chemoresistance in some cell lines. It would therefore be useful to identify markers that predict whether a specific cell line or tumor will undergo apoptosis when stimulated with CD40 and to ...
A collection of disease information resources and questions answered by our Genetic and Rare Diseases Information Specialists for Primary cutaneous follicle center lymphoma
TY - JOUR. T1 - Cutaneous lymphoid hyperplasia and marginal zone B-cell lymphoma following vaccination. AU - May, Steve A.. AU - Netto, George. AU - Domiati-Saad, Rana. AU - Kasper, Candace. PY - 2005/9. Y1 - 2005/9. N2 - Atypical lymphoid infiltrations arose within the influenza inoculation sites of two adult female patients. One patient developed a low-grade cutaneous marginal zone B-cell lymphoma (MZL) that was responsive to local excision and radiation therapy despite spread to a distant cutaneous site. The second patients clinical course was characterized by a locally aggressive, histologically reactive inflammatory reaction responsive only to radiation therapy after multiple failed attempts at surgical resection.. AB - Atypical lymphoid infiltrations arose within the influenza inoculation sites of two adult female patients. One patient developed a low-grade cutaneous marginal zone B-cell lymphoma (MZL) that was responsive to local excision and radiation therapy despite spread to a distant ...
In diffuse large B-cell lymphoma, first-line treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; salvage with cisplatin-based regimens for relapsing patients; and autologous stem cell therapy are standards of care. Treatment approaches are less clear for patients who are refractory or who are not candidates for autologous stem cell therapy. Options may include palliative regimens or clinical trial enrollment. One therapy under investigation in diffuse large B-cell lymphoma is lenalidomide, an immunomodulatory agent with antiangiogenic activity. We present the case of a 55-year-old Caucasian male patient diagnosed with diffuse large B-cell lymphoma who had an early relapse after treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. He then had a subsequent early relapse after cisplatin-based salvage consolidated with autologous stem cell therapy. The efficacy of gemcitabine-cisplatin-rituximab was limited to five months, followed by
1 of 2 NCCN QUICK GUIDE tm Diffuse Large B-cell Lymphoma, 2017 This NCCNQUICK GUIDE tm sheet summarizes key points from the complet e NCCN Guidelines for Patients ® : Diffuse Large B-cell Lymphoma . T hese guidelines explain which tests and treatments are recommended by experts in cancer. To view and download the guidelines, visit NCC N.or g/patients or, to order printed copies, visit Amazon.com What is diffuse large B-cell lymphoma (DLBCL)? Lymphoma is a cancer of white blood cells called lymphocytes that are within the lymphatic system. This system transports fluids to the bloodstream and fights germs. DLBCL is a cancer of B-cells that are from within or have been released by germinal centers of lymphatic organs. 9 How is DLBCL diagnosed? Tissue from the tumor will likely be removed with an incisional or excisional biopsy. A doctor will test the tissue to look for a pattern of proteins on the cells surface that is common to DLBCL. 10 What health care is needed before treatment? A report of ...
FOSTER CITY, Calif. & SANTA MONICA, Calif.-(BUSINESS WIRE)-Kite, a Gilead Company, (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted regular approval to Yescarta™ (axicabtagene ciloleucel), the first chimeric antigen receptor T cell (CAR T) therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma (transformed follicular lymphoma, or TFL). Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma.. CAR T therapy is a breakthrough in hematologic cancer treatment in which a patients own T cells are engineered to seek and destroy cancer cells. CAR T therapy is manufactured specifically for each individual patient.. The FDA approval of ...
TY - JOUR. T1 - Germinal center and activated B-cell profiles separate Burkitt lymphoma and diffuse large B-cell lymphoma in AIDS and non-AIDS cases. AU - Gormley, Robert P.. AU - Madan, Rashna. AU - Dulau, Alina E.. AU - Xu, Dongsheng. AU - Tamas, Ecaterina F.. AU - Bhattacharyya, Pritish K.. AU - LeValley, Aaron. AU - Xue, Xiaonan. AU - Kumar, Pankaj. AU - Sparano, Joseph. AU - Ramesh, K. H.. AU - Pulijaal, Venkat. AU - Cannizzaro, Linda. AU - Walsh, Daniel. AU - Ioachim, Harry L.. AU - Ratech, Howard. PY - 2005/11. Y1 - 2005/11. N2 - Morphologic features of Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) overlap. No single phenotypic marker or molecular abnormality is pathognomonic. We tested a panel of 8 germinal center (GC) and activated B-cell (ABC) markers for their ability to separate BL and DLBCL. We diagnosed 16 BL and 39 DLBCL cases from 21 patients with AIDS and 34 without AIDS based on traditional morphologic criteria, Ki-67 proliferative index, and c-myc ...
MalaCards based summary : Splenic Diffuse Red Pulp Small B-Cell Lymphoma, also known as splenic diffuse red pulp lymphoma, is related to b-cell lymphoma and hairy cell leukemia. An important gene associated with Splenic Diffuse Red Pulp Small B-Cell Lymphoma is BCOR (BCL6 Corepressor), and among its related pathways/superpathways are GPCR Pathway and PI3K-Akt signaling pathway. Affiliated tissues include b cells, bone and t cells, and related phenotypes are cardiovascular system and embryo ...
Yogi Berra offered the comment Its déjà vu all over again when he witnessed Mickey Mantle and Roger Maris repeatedly hitting back-to-back home runs in the early 1960s. His pithy remark neatly summarizes my reaction when I read the article, Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma, by Drs. Dunleavy, Wilson, and colleagues in The New England Journal of Medicine.1. The report nicely caps more than a decade of clinical investigation carried out by Dr. Wilsons group at the National Cancer Institute, focused on the use of infusional immunochemotherapy to treat various aggressive non-Hodgkin lymphomas (see a summary of the report in this issue of The ASCO Post). Briefly, this group demonstrated that when they used dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab [Rituxan]) to treat primary mediastinal large B-cell lymphoma in 51 patients, almost all of the patients appeared to have been cured. ...
TY - JOUR. T1 - A case of rectal squamous cell carcinoma with metachronous diffuse large B cell lymphoma in an HIV-infected patient. AU - Choi, Heun. AU - Lee, Hye Won. AU - Ann, Hea Won. AU - Kim, Jae Kyung. AU - Kang, Hua Pyong. AU - Kim, Sun Wook. AU - Ku, Nam Su. AU - Han, Sang Hoon. AU - Kim, June Myung. AU - Choi, Jun Yong. N1 - Publisher Copyright: © 2014 by The Korean Society of Infectious Diseases,Korean Society for Chemotherapy.. PY - 2014. Y1 - 2014. N2 - Diffuse large B cell lymphoma (DLBCL) is one of the most common acquired immune deficiency syndrome (AIDS)-defining malignancies among human immunodeficiency virus -infected patients, and rectal cancer has recently emerged as a prevalent non-AIDS-defining malignancy. We report a case of rectal squamous cell carcinoma that was metachronous with DLBCL in an HIV-infected patient who was receiving highly active antiretroviral therapy. The patient was diagnosed with DLBCL and showed complete remission after chemotherapy. Follow-up ...
NICE has published final guidance which recommends tisagenlecleucel (Kymriah) therapy for use within the Cancer Drugs Fund as an option for treating relapsed or refractory diffuse large B-cell lymphoma in adults after two or more systemic therapies, only if the conditions in the managed access agreement are followed. There is no standard treatment for relapsed or refractory diffuse large B-cell lymphoma after two or more systemic therapies. Salvage chemotherapy (that is, chemotherapy to control the disease) is the most common treatment option. Evidence from a single-arm study with short follow-up and a small observational study suggests that people having tisagenlecleucel may live for longer or have more time before their disease relapses. But longer follow-up from the study is needed and there are no data directly comparing tisagenlecleucel with salvage chemotherapy. To assess the comparative effectiveness of tisagenlecleucel and salvage chemotherapy, data from the first CORAL extension study ...
1. Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018;50:74-87 2. Kubuschok B, Held G, Pfreundschuh M. Management of diffuse large B-cell lymphoma (DLBCL). Cancer treatment and research. 2015;165:271-88 3. Flowers CR, Sinha R, Vose JM. Improving outcomes for patients with diffuse large B-cell lymphoma. CA: a cancer journal for clinicians. 2010;60:393-408 4. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI. et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. The New England journal of medicine. 2002;346:1937-47 5. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-11 6. Wight JC, Chong G, Grigg AP, Hawkes EA. Prognostication of diffuse large B-cell lymphoma in the molecular era: moving beyond the IPI. Blood reviews. 2018;32:400-15 7. Wang XJ, Medeiros LJ, Bueso-Ramos CE, ...
Researchers from the NYU Cancer Institute, an NCI-designated cancer center at NYU Langone Medical Center, have discovered a new potential therapeutic target for Diffuse Large B-Cell Lymphoma (DLBCL), the most aggressive and common type of lymphoma in adults. The new study, published in the November 23 issue of Nature, reveals the underlying molecular mechanism contributing to the development of lymphomagenesis. We have discovered that the protein FBXO11 is a novel tumor suppressor in B-cells, said senior study author Michele Pagano, MD, the May Ellen and Gerald Jay Ritter Professor of Oncology and Professor of Pathology at NYU Langone Medical Center and a Howard Hughes Medical Institute Investigator. Our new research findings show deletion or mutation of the FBXO11 gene in B-cells may lead to the formation of Diffuse Large B-Cell Lymphoma. Lymphoma is a blood cancer that affects the lymphatic system, the bodys infection and disease-fighting network. DLBCL is the most common type of adult ...
AIMS: To assess the value of flow cytometry (FCM) in the diagnosis and classification of reactive lymphoid hyperplasia and malignant lymphoma by fine needle aspiration (FNA) cytology. METHODS: Forty six fine needle aspirates of lymphoproliferative disorders were examined by FCM as well as routine cytological assessment. An immunoglobulin light chain ratio (LCR) was calculated for clonality analysis. Additional immunophenotyping was performed in 15 cases. RESULTS: All 25 cases of reactive lymphoid hyperplasia were polyclonal by FCM (LCR , 2/1); 17 of 20 cases of B cell non-Hodgkins lymphoma were monoclonal (LCR , 3/1). Analysis of cells based on size facilitated detection of small populations of clonal neoplastic cells. Analysis of CD5, CD10, and CD23 expression by FCM facilitated subclassification of mantle cell lymphoma, small lymphocytic lymphoma, and some lymphomas of follicle centre cell origin. One case of T cell non-Hodgkins lymphoma was correctly classified by FCM. CONCLUSIONS: FNA ...
BACKGROUND: Germinal center-derived B cell lymphomas are tumors of the lymphoid tissues representing one of the most heterogeneous malignancies. Here we characterize the variety of transcriptomic … phenotypes of this disease based on 873 biopsy specimens collected in the German Cancer Aid MMML (Molecular Mechanisms in Malignant Lymphoma) consortium. They include diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), Burkitts lymphoma, mixed FL/DLBCL lymphomas, primary mediastinal large B cell lymphoma, multiple myeloma, IRF4-rearranged large cell lymphoma, MYC-negative Burkitt-like lymphoma with chr. 11q aberration and mantle cell lymphoma. METHODS: We apply self-organizing map (SOM) machine learning to microarray-derived expression data to generate a holistic view on the transcriptome landscape of lymphomas, to describe the multidimensional nature of gene regulation and to pursue a modular view on co-expression. Expression data were complemented by pathological, genetic and ...
In this study we assessed the prognostic significance of absolute monocyte count and elected the best cut-off value at diagnosis, in a large cohort of patients with diffuse large B-cell lymphoma. Data were retrieved for therapy-naive patients with diffuse large B-cell lymphoma followed in Israel and Italy during1993-2010. A final cohort of 1017 patients was analyzed with a median follow up of 48 months and a 5 year overall survival rate of 68%. The best absolute monocyte count cut-off level was, 630/mm3and the 5 years overall survival for these patients was 71% and 59% for those with ,630mm3 (p=0.0002). Of the 1017 patients, 521 (51%) were treated with chemo-immunotherapy, and in this cohort, using multivariate analysis, elevated monocyte counte retained a negative prognostic value even when adjusted for IPI (HR 1.54, P=0.009). This large study shows that a simple parameter like absolute monocyte count (,630 /mm3) can easily be used routinely in the evaluation of newly diagnosed diffuse large ...
Cladribine is a purine nucleoside analog used to treat B-cell chronic lymphocytic leukemia and hairy cell leukemia, also functions as an inhibitor of DNA synthesis to block the repair of the damaged DNA. The therapeutic role of cladribine against diffuse large B-cell lymphoma cells (DLBCL) is still undefined. In the present study, we demonstrated that cladribine inhibited cell proliferation and induced G1 phase arrest in human DLBCL cells. Furthermore, we showed that cladribine induced apoptosis by decreasing the expression of c-FLIPL and increasing the expression of DR4 and the cleaved form of caspase8. Cladribine also upregulated the expression of Bax, and downregulated the expression of Mcl-1 and Bcl-2 in a dose-dependent manner. It also activated endoplasmic reticulum (ER) stress, and ATF4 expression was required for cladribine induced apoptosis. Also, we showed that suberoylanilide hydroxamic acid (SAHA) enhanced the pro-apoptotic role of cladribine. Collectively, cladribine activated ...
We recently demonstrated that the prognosis for de novo CD5-positive (CD5+) diffuse large-B-cell lymphoma (DLBCL) is markedly worse than that for CD5-negative (CD5-) DLBCL. Our findings also suggested that on the basis of its clinical features CD5+ DLBCL may constitute a unique disease category. How …
Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2015 Summary Global Markets Direct s, Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2015, provides...
Site: Primary cardiac lymphoma typically involves the right atrium, as a mass and is often associated with pericardial effusion. Involvement of the other chambers is less common. Most patients have pericardial involvement, but extension into the valves is rare. Reporting of Cardiac Tumours Type of Primary cardiac lymphomas : Non Hodgkins Type: (mostly of B-cell nature) - Low ; Intermediate ; High grade Microscopic diagnosis is based on the same criteria as applied in lymphomas in general. Case Link (NEJM) Cardiac lymphomas demonstrate a wide range of histologic types, including well-differentiated B-cell lymphomas, follicular center cell lymphomas, diffuse large cell lymphomas, and undifferentiated Burkitt-like lymphomas.. The tumour usually infiltrate the surrounding muscle and epicardial fat . In some cases it may infiltrate the adventitia of the coronary arteries.. Reporting of Endomyocardial Biopsy Diagnosis of lymphoma after cardiac transplantation should be done carefully, as there are ...
Radioimmunotherapy treatment with Zevalin® (ibritumomab tiuxetan) is safe and effective in high-risk elderly patients with diffuse large B-cell lymphoma, according to the results of a study published in Clinical Cancer Research. Non-Hodgkins lymphoma (NHL) refers to a group of cancers that originate in different cells of the immune system. Diffuse large B-cell NHL is a common type of NHL that affects immune cells called B-cells; it is considered an aggressive type of NHL.. Standard treatment for DLBCL typically includes R-CHOP, which refers to treatment with the monoclonal antibody Rituxan® (rituxamab) plus cyclophosphamide/Adriamycin/vincristine/prednisone (CHOP). Although this regimen has led to improved outcomes, there is a group of poor-risk patients who need an alternative treatment strategy.. Zevalin is a type of radioimmunotherapy treatment (RIT) that combines the monoclonal antibody Rituxan with Zevalin, which is comprised of an anti-CD20 monoclonal antibody and Yttrium-90, a ...
Mantle cell lymphoma is a mature lymphoid neoplasm characterized by the t(11;14)(q13;q32) and cyclin D1 overexpression. SOX11 is a transcription factor commonly overexpressed in these tumors but absent in most other mature B-cell lymphomas whose function is not well understood. Experimental studies have shown that silencing of SOX11 in mantle cell lymphoma cells promotes the shift from a mature B cell into an early plasmacytic differentiation phenotype, suggesting that SOX11 may contribute to tumor development by blocking the B-cell differentiation program. The relationship between SOX11 expression and terminal B-cell differentiation in primary mantle cell lymphoma and its relationship to the plasmacytic differentiation observed in occasional cases is not known. In this study we have investigated the terminal B-cell differentiation phenotype in 60 mantle cell lymphomas, 41 SOX11-positive and 19 SOX11-negative. Monotypic plasma cells and lymphoid cells with plasmacytic differentiation expressing ...
Introduction: Diffuse large B-cell lymphoma (DLBCL), not otherwise specified, is a large B-cell lymphoma with a diffuse growth pattern and aggressive clinical course. It is divided in subgroups according to its morphology, immunophenotype, and primary site. Dissemination to bone marrow occurs in 11% to 35% of cases and can be of concordant or discordant morphology. Objective: To examine the association, the type of bone marrow involvement in relation to the primary site, morphology, immunohistochemistry of DLBCLs and to determine the cases of Epstein-Barr virus positive DLBCLs. Materials and Methods: We reviewed lymph node and extranodal biopsies as well as the respective bone marrow biopsies in all cases of DLBCL diagnosed in the Hospital General de México during the period from 2002 to 2010. We used immunohystochemistry for immunophenotype identification (Hanss algorithm) and an in-situ hybridization technique to detect presence of Epstein Barr encoded RNA (EBER). Results: We included 108 patients
Addition of rituximab (R) to CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy improved outcome for diffuse large B-cell lymphoma (DLBCL) patients. Approximately 40% of patients who receive R-CHOP still succumb to disease due to intrinsic resistance or relapse. A potential negative regulator of DLBCL treatment outcome is the CD47 dont eat me immune checkpoint. To delineate the impact of CD47, we used a clinically and molecularly well-annotated cohort of 939 DLBCL patients, comprising both germinal center B-cell (GCB) and non-GCB DLBCL subtypes, treated with either CHOP or R-CHOP. High (above median) CD47 mRNA expression correlated with a detrimental effect on overall survival (OS) when DLBCL patients received R-CHOP therapy (P = 0.001), but not CHOP therapy (P = 0.645). Accordingly, patients with low CD47 expression benefited most from the addition of rituximab to CHOP [HR, 0.32; confidence interval (CI), 0.21-0.50; P ,0.001]. This negative impact of high CD47 ...
Global Markets Directs, Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2014, provides an overview of the Diffuse Large B-Cell Lymphomas therapeutic pipeline. This report provides
Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2016SummaryGlobal Markets Directs, Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2016, provides ...
Kite Pharma has created engineered cell therapies that express either a chimeric antigen receptor (CAR) or an engineered T-cell receptor (TCR), based on the type of cancer.. The companys primary CAR T therapy candidate, axicabtagene ciloleucel (axi-cel), is expected to be the first available treatment for refractory aggressive non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL).. Kite Pharma president, chairman and CEO Dr Arie Belldegrun said: CAR T has the potential to become one of the most powerful anti-cancer agents for hematologic cancers.. Axicabtagene ciloleucel is currently under priority review by the US Food and Drug Administration (FDA).. A marketing authorisation application (MAA) has also been filed with the European Medicines Agency (EMA) for axi-cel for the treatment of relapsed / refractory DLBCL, TFL and PMBCL.. The approval in Europe is expected in 2018.. ...
Arber DA, Simpson JF, Weiss LM, et al. Non-Hodgkins lymphoma involving the breast. Am J Surg Pathol 1994;18:288-95. Jeanneret-Sozzi W, Taghian A, Epelbaum R, et al. Primary breast lymphoma: Patient pro le, outcome and prognostic factors. A multicentre rare cancer network study. BMC Cancer 2008;8:86. Wiseman C, Liao KT. Primary lymphoma of the breast. Cancer 1972;29:1705-12. Brustein S, Filippa DA, Kimmel M, et al. Malignant lymphoma of the breast. A study of 53 patients. Ann Surg 1987;205:144-50. Ganjoo K, Advani R, Mariappan MR, et al. Non-Hodgkin lymphoma of the breast. Cancer 2007;110:25-30. Ryan G, Martinelli G, Kuper-Hommel M, et al. Primary diffuse large B-cell lymphoma of the breast: Prognostic factors and outcomes of a study by the international extranodal lymphoma study group. Ann Oncol 2008;19:233-41. Dawn B, Perry MC. Bilateral non-Hodgkins lymphoma of the breast mimicking mastitis. South Med J 1997;90:328-9. Fukuhara S, Watanabe T, Munakata W, et al. Bulky disease has an impact on ...
TY - JOUR. T1 - IL-25 dampens the growth of human germinal center-derived B-cell non Hodgkin Lymphoma by curtailing neoangiogenesis. AU - Ferretti, Elisa. AU - Di Carlo, Emma. AU - Ognio, Emanuela. AU - Fraternali-Orcioni, Giulio. AU - Corcione, Anna. AU - Belmonte, Beatrice. AU - Ravetti, Jean Louis. AU - Tripodo, Claudio. AU - Ribatti, Domenico. AU - Pistoia, Vito. PY - 2017. Y1 - 2017. N2 - Interleukin (IL)-25, a member of the IL-17 cytokine superfamily, is produced by immune and non-immune cells and exerts type 2 pro-inflammatory effectsin vitroandin vivo. The IL-25 receptor(R) is composed of the IL-17RA/IL-17RB subunits. Previous work showed that germinal centre (GC)-derived B-cell non Hodgkin lymphomas (B-NHL) expressed IL-17AR, formed by IL-17RA and IL-17RC subunits, and IL-17A/IL-17AR axis promoted B-NHL growth by stimulating neoangiogenesis. Here, we have investigated expression and function of IL-25/IL-25R axis in lymph nodes from human GC-derived B-NHL, i.e. Follicular Lymphoma (FL,10 ...
In 27% of diffuse large B cell lymphoma (DLBCL) cases, bone marrow (BM), assessed by BM biopsy, is involved. BM involvement, an extranodal site …
Diffuse large B-cell lymphoma (DLBCL) shows a higher incidence in males versus females. Epidemiological studies have shown that female gender is a favorable prognostic factor, which may be explained by estrogens. Here we show that when grafting human DLBCL cells to immunocompromised mice, tumor growth in males is faster. When treating mice grafted with either germinal center or activated B-cell like DLBCL cells with the selective estrogen receptor β (ERβ) agonist diarylpropionitrile, tumor growth was significantly inhibited. Furthermore, nuclear ERβ1 expression analysis in primary DLBCLs by immunohistochemistry revealed expression in 89% of the cases. Nuclear ERβ1 expression was in a univariate and multivariate analysis, an independent prognostic factor for adverse progression-free survival in Rituximab-chemotherapy treated DLBCL (p = 0.02 and p = 0.04, respectively). These results suggest that estrogen signaling through ERβ1 is an interesting future therapeutic target for treatment of ...
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma and displays heterogeneous clinical and molecular characteristics. In this study, high throughput gene expression profiling of DLBCL tumor samples was used to design a 12-gene expression-based risk score (GERS) predictive for patients overall survival. GERS allowed identifying a high-risk group comprising 46,4% of the DLBCL patients in two independent cohorts (n=414 and n=69). GERS was shown to be an independent predictor of survival when compared to the previously published prognostic factors, including the International Prognostic Index (IPI). GERS displayed a prognostic value in germinal-center B-cell-like subgroup (GCB) and activated B cell-like (ABC) molecular subgroups of patients as well as in DLBCL patients treated with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) or Rituximab-CHOP (R-CHOP) regimens. Combination of GERS and IPI lead to a potent prognostic classification of DLBCL patients.
The activated B cell (ABC-like) subtype of diffuse large B cell lymphoma (DLBCL) is characterized by chronic activation of signaling initiated by immunoglobulin μ (IgM). By analyzing the DNA copy number profiles of 1000 DLBCL tumors, we identified gains of 18q21.2 as the most frequent genetic alteration in ABC-like DLBCL. Using integrative analysis of matched gene expression profiling data, we found that the TCF4 (E2-2) transcription factor gene was the target of these alterations. Overexpression of TCF4 in ABC-like DLBCL cell lines led to its occupancy on immunoglobulin (IGHM) and MYC gene enhancers and increased expression of these genes at the transcript and protein levels. Inhibition of TCF4 activity with dominant-negative constructs was synthetically lethal to ABC-like DLBCL cell lines harboring TCF4 DNA copy gains, highlighting these gains as an attractive potential therapeutic target. Furthermore, the TCF4 gene was one of the top BRD4-regulated genes in DLBCL cell lines. BET ...